Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.55 |
| ▸ | PPARA | Q07869 | 14/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8559317 | 1.00 | PPARG (0.55) | PPARGPPARAGRIK1GRIK2SMN1; SMN2 | |
| SCHEMBL8558724 | 1.00 | PPARG (0.55) | PPARGPPARAGRIK1GRIK2SMN1; SMN2 | |
| SCHEMBL8560351 | 0.87 | PPARG (0.59) | PPARGPPARAGRIK1GRIK2SMN1; SMN2 | |
| SCHEMBL8559217 | 0.85 | PPARG (0.53) | PPARGPPARA | |
| SCHEMBL8559220 | 0.85 | PPARG (0.53) | PPARGPPARA | |
| SCHEMBL8564253 | 0.84 | GRIK1 (0.49) | PPARGPPARAGRIK1GRIK2SMN1; SMN2 | |
| SCHEMBL8564248 | 0.84 | GRIK1 (0.49) | PPARGPPARAGRIK1GRIK2SMN1; SMN2 | |
| SCHEMBL8561497 | 0.83 | PPARG (0.63) | PPARGPPARA | |
| SCHEMBL8561508 | 0.83 | PPARG (0.63) | PPARGPPARA | |
| SCHEMBL8564512 | 0.83 | PPARG (0.63) | PPARGPPARAGRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5843997-A | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1998-12-01 | — | — | US | claimed |
| US-5576323-A | CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1996-11-19 | — | — | US | claimed |
| US-5843997-A | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1998-12-01 | — | — | US | disclosed |
| US-5576323-A | CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1996-11-19 | — | — | US | disclosed |